Korean J Physiol Pharmacol The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology Korean J. Physiol. Pharmacol. 1226-4512 2093-3827 The Korean Physiological Society and The Korean Society of Pharmacology 10.4196/kjpp.2022.26.5.377 kjpp-26-5-377 Original Article Anti-cancer effects of fenbendazole on 5-fluorouracil-resistant colorectal cancer cells ParkDeokbae 1 # LeeJung-Hee 2 # YoonSang-Pil 3 * Department of Histology, College of Medicine, Jeju National University, Jeju 63243, Korea Department of Cellular and Molecular Medicine, Chosun University School of Medicine, Gwangju 61452, Korea Department of Anatomy, College of Medicine, Jeju National University, Jeju 63243, Korea Correspondence Sang-Pil Yoon, E-mail: spyoon@jejunu.ac.kr

These authors contributed equally to this work.

Author contributions: D.P. and S.P.Y. conceived and designed the present study; D.P. and J.H.L. performed the experiments for data acquisition and analysis; D.P. and J.H.L. interpreted the experimental results; D.P. and J.H.L. wrote the original manuscript; S.P.Y. revised the manuscript.

 1 9 2022 1 9 2022 26 5 377 387 25 5 2022 7 6 2022 20 6 2022 Copyright © Korean J Physiol Pharmacol 2022 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Benzimidazole anthelmintic agents have been recently repurposed to overcome cancers resistant to conventional therapies. To evaluate the anti-cancer effects of benzimidazole on resistant cells, various cell death pathways were investigated in 5-fluorouracil-resistant colorectal cancer cells. The viability of wild-type and 5-fluorouracil-resistant SNU-C5 colorectal cancer cells was assayed, followed by Western blotting. Flow cytometry assays for cell death and cell cycle was also performed to analyze the anti-cancer effects of benzimidazole. When compared with albendazole, fenbendazole showed higher susceptibility to 5-fluorouracil-resistant SNU-C5 cells and was used in subsequent experiments. Flow cytometry revealed that fenbendazole significantly induces apoptosis as well as cell cycle arrest at G2/M phase on both cells. When compared with wild-type SNU-C5 cells, 5-fluorouracil-resistant SNU-C5 cells showed reduced autophagy, increased ferroptosis and ferroptosis-augmented apoptosis, and less activation of caspase-8 and p53. These results suggest that fenbendazole may be a potential alternative treatment in 5-fluorouracil-resistant cancer cells, and the anticancer activity of fenbendazole does not require p53 in 5-fluorouracil-resistant SNU-C5 cells.

 Apoptosis Colorectal cancer Drug resistance Fenbendazole p53 INTRODUCTION

Drug repositioning of approved therapies might extend their therapeutic potential against resistant cancer cells [1]. Benzimidazole anthelmintic agents are relatively non-toxic to normal cells [2-6] with a half-maximal inhibitory concentration (IC50) of 5 µM for less sensitivity in 461 cancer cells [7]. A recent report summarized the anti-tumourigenic activity of benzimidazole as follows [1]: 1) cell cycle arrest at G2/M phase with increased levels of cyclin B1, p21 and p27Kip1; 2) apoptosis with increased expression of caspase-3, poly (ADP-ribose) polymerase (PARP), and cytochrome-C; 3) autophagy with increased microtubule-associated protein 1A/1B-light chain 3 (LC3) and Beclin-1; and 4) altered cell viability or differentiation with increased p53, p21, p38, and c-Jun N-terminal kinase (JNK), and decreased extracellular signal-regulated protein kinase (ERK).

Self-administration of fenbendazole, a benzimidazole anthelmintic agent, by patients with cancer has been reported in social media [8,9]. Although anti-cancer effects of fenbendazole as an alternative or supplementary agent were recently reported in a case series of genitourinary malignancies [10], no definitive evidence of anti-cancer effects exists in human because of its toxicity and teratogenicity [8]. Nevertheless, the potential for drug repositioning of fenbendazole requires further investigation because of the much higher IC50 values in normal cells compared with cancer cells [5].

Colorectal cancer (CRC) is the third most common cancer diagnosed and the second leading cause of cancer death worldwide [11]. Although 5-fluorouracil (5-FU) remains the mainstay of standard chemotherapy for CRC, various resistance mechanisms are reported [12]. Especially, mutations in p53 [13-15] or p38α mitogen-activated protein kinase (MAPK) [16,17] are associated with chemo-resistant CRC. To overcome the resistance, activation of transforming growth factor-β [18] or ERK [19] was suggested in 5-FU-resistant CRC cell line. Upregulation of protein kinase B (Akt) is a critical factor in the progression of CRC [13]. It induces apoptosis via inhibition of rapidly accelerated fibrosarcoma (a family of three serine/threonine-specific protein kinases) – ERK activation [20].

In terms of benzimidazole, Nygre et al. [21] screened a compound library to identify agents with potential for repositioning in cancer therapy, and found that mebendazole and albendazole have anti-cancer activity in 80% of CRC cell lines. Benzimidazole inhibited the proliferation of HCT116 cells [22] and induced apoptosis via activated JNK in HCT116 and SW480 cells [23]. Flubendazole induced mitotic catastrophe with increased cyclin B1 and caspase-3-PARP pathway [24]. It has an anti-migratory effect by inhibiting the expression of nuclear factor kappa-light-chain-enhancer of activated B cells p65 in CRC cells derived from primary tumor and lymph node metastasis [25]. In addition, Williamson et al. [26] showed that mebendazole combined with non-steroidal anti-inflammatory drugs reduced tumor initiation by decreasing c-Myc and increasing apoptosis in an ApcMin/+ mouse model of familial adenomatous polyposis.

Although fenbendazole enhance the cytotoxicity of radiation or docetaxel and increased the anti-cancer effects of radiation against mammary tumors [27], only a few studies evaluated at the anti-cancer effects of benzimidazole against metastatic or resistant cancers [28-30]. Albendazole effectively inhibited paclitaxel- and doxorubicin-resistant lung cancer cells [31] and thereby reduced multidrug resistance. Nonetheless, the role of benzimidazole in resistant CRC has yet to be reported. Therefore, we aimed to evaluate the effects and underlying mechanisms of fenbendazole in SNU-C5/5-FUR cells as compared with wild type SNU-C5 cells in order to identify therapeutic strategies to overcome resistance to 5-FU.

 METHODS Reagents and antibodies

MTT was purchased from Amresco, Inc. (VWR International LLC, Seongnam, Korea). 5-fluorouracil (5-FU, #F6627), albendazole (#PHR 1281), deferoxamine mesylate (DFOM, #D9533), fenbendazole (#PHR 1832), and ferrostatin-1 (#SML 0583) were obtained from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany).

Antibodies specific for c-Myc (9E10; #sc-40; diluted 1:1,000), cytochrome-C (H-104; #sc-7159; diluted 1:1,000), ERK (C-16; #sc-93; diluted 1:2,000), ferritin heavy chain (B-12) (FTH1; #sc-376594; diluted 1:2,000), GAPDH (#sc-47724; diluted 1:2,000), and phospho-p53 (Ser6; #sc135630; diluted 1:1,000), transferrin receptor (H68.4) (TfRC; #sc-65882; diluted 1:2,000) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA); glutathione peroxidase 4 (GPX4 [EPNCIR144]; #ab125066; diluted 1:1,000) and SLC40A1 (ferroportin, FPN; #ab78066; diluted 1:1,000) were purchased from Abcam (Cambridge, UK); caspase-3 (#9665; diluted 1:1,000), cleaved caspase-3 (#9661; diluted 1:1,000), cyclin B1 (#4138; diluted 1:1,000), phospho-ERK (Thr202/Tyr204; #4370; diluted 1:2,000), JNK (#9252; diluted 1:1,000), phosphor-JNK (Thr183/Tyr185) (#9251; diluted 1:1,000), p21 (#2947; diluted 1:1,000), p27 (#2552; diluted 1:1,000), p38 MAPK (#9212; diluted 1:1,000), phospho-p38 MAPK (Thr180/Tyr182; #9211; diluted 1:1,000), PARP (#9542; diluted 1:1,000), autophagy antibody sampler kit (#4445; consisting of Beclin-1 (D40C5), LC3 (D3U4C), Atg5 (D5F5U), Atg12 (D88H11), Atg16L1 (D6D5), Atg7 (D12B11), and Atg3; diluted 1:2,000/each), and necroptosis antibody sampler kit (#98110; consisting of receptor-interacting protein kinase (RIP) (D94C12), phospho-RIP (Ser166) (D1L3S), mixed lineage kinase domain-like protein (MLKL) (D2I6N), phospho-MLKL (Ser358) (D6H3V), receptor-interacting protein kinase 3 (RIP3) (E1Z1d), and phospho-RIP3 (S227) (D6W2T); diluted 1:1,000/each) were purchased from Cell Signaling Technology Inc. (Beverly, MA, USA); the high mobility group box 1 (HMGB1; #GTX62170; diluted 1:2,000) and p53 (#GTX70218; diluted 1:1,000) were purchased from GeneTex (Irvine, CA, USA); SLC7A11 (cysteine/glutamate transporter ; #ANT-111; diluted 1:2,000) was purchased from Alomone Labs (Jerusalem, Israel).

 Cell culture and viability assay

SNU-C5 (IC50 against 5-FU = 5 μM) and the 5-fluorouracil-resistant SNU-C5 (SNU-C5/5-FUR; IC50 against 5-FU = 140 μM) cell lines were cultured as previously described [19,32].

To achieve similar confluency after 3 days of incubation, SNU-C5 (2 × 103 cells/well) and SNU-C5/5-FUR (5 × 103 cells/well) cells were seeded in 96-well plates. Cells were treated with benzimidazole (fenbendazole and albendazole) and anti-ferroptotic agents (ferrostatin-1 and DFOM) at various concentrations. The effect of drugs on cell viability was evaluated via reduction of MTT to its formazan product with a VERSAmax microplate reader (Molecular Devices Korea LLC, Seoul, Korea) as previously reported [19].

 Flow cytometry

Cells were treated with or without fenbendazole (0.5 and 5.0 μM for SNU-C5 and SNU-C5/5-FUR cells, respectively) for 3 days, followed by flow cytometry using the FACSCalibur system (BD Biosciences, San Jose, CA, USA) and BD FACStation software version 6.0 (BD Biosciences) as described previously [19,32].

 Western blotting analysis

The harvest, the protein quantification, and electrophoresis of the protein in cell lysates were performed as previously described [19,32]. The protein bands were captured and quantified using AzureSpot analysis software (version 14.2; Azure c300; Azure Biosystems, Inc., Dublin, CA, USA).

 Statistical analysis

All data were compiled from a minimum of three replicate experiments. The data are expressed as mean values ± SD. Statistically significant differences (p < 0.05) were found using Student’s paired t-test or one-way analysis of variance (ANOVA) with a Bonferroni post-hoc test (SPSS version 14.0; SPSS Inc., Chicago, IL, USA).

 RESULTS Benzimidazole induced dose- and time-dependent anti-proliferative effects

Fenbendazole and albendazole showed dose-dependent anti-proliferative effects against both SNU-C5 and SNU-C5/5-FUR cells (Fig. 1A, C). After 3 days of incubation, the IC50 values of the SNU-C5 cells treated with fenbendazole and albendazole were 0.50 and 0.47 μM, respectively. The IC50 values of SNU-C5/5-FUR cells treated with fenbendazole and albendazole were 4.09 and 4.23 μM, respectively. Cell viability of SNU-C5 cells was s 42.24 ± 2.71% and 38.18 ± 2.01% when incubated with 1 μM of fenbendazole and albendazole, respectively. Cell viability of SNU-C5/5-FUR cells was 65.66 ± 1.83% and 67.57 ± 1.58% when treated with 1 μM of fenbendazole and albendazole, respectively, which was further decreased to 30.79 ± 2.35% and 39.78 ± 1.40% at 10 μM concentrations.

Fenbendazole was more effective than albendazole against SNU-C5/5-FUR cells, and time-dependent anti-cancer effects of fenbendazole were further evaluated (Fig. 1B, C). Fenbendazole showed time-dependent anti-proliferative effects on both CRC cells. During 3 days of incubation, the proliferation of SNU-C5 cells increased 4.07 ± 0.18-fold with vehicle and 1.63 ± 0.11-fold with 1 μM of fenbendazole when compared with vehicle-treated control. During 3 days of incubation, SNU-C5/5-FUR cells proliferated 4.60 ± 0.41-fold with vehicle, and 2.94 ± 0.25 and 1.44 ± 0.15-fold with 1 μM and 10 μM of fenbendazole, respectively, when compared with vehicle-treated control. Taken together, a dose of close to the IC50 values of fenbendazole, 0.5 μM for SNU-C5 cells and 5 μM for SNU-C5/5-FUR cells, was used in subsequent experiments.

 Fenbendazole induced cell cycle arrest at G2/M phase with increased p21 expression on CRC cells

Cell cycle analysis resulted in a significant increase in the fraction of G2/M phase (Fig. 2A). The fraction of SNU-C5 (12.50 ± 0.92% vs. 21.07 ± 1.10%) and SNU-C5/5-FUR (24.24 ± 0.28% vs. 84.30 ± 1.66%) cells in the G2/M phase showed a significant upward trend, while the fraction of SNU-C5 (56.40 ± 0.69% vs. 52.20 ± 0.38%) and SNU-C5/5-FUR (39.53 ± 0.39% vs. 3.55 ± 0.13%) cells in the G0/G1 phase showed a significant downward trend. The proportion of S phase considerably decreased in SNU-C5 (29.91 ± 0.30% vs. 25.12 ± 0.77%) and SNU-C5/5-FUR (36.23 ± 0.24% vs. 12.15 ± 1.61%) cells.

Western blot revealed that p27 showed a significant increase in the number of SNU-C5 (2.82 ± 0.04-fold) and SNU-C5/5-FUR (2.43 ± 0.17-fold) cells. P21 expression was significantly increased in SNU-C5 (1.98 ± 0.07-fold) and SNU-C5/5-FUR (1.68 ± 0.13-fold) cells. Levels of c-Myc decreased considerably in SNU-C5 (0.59 ± 0.07-fold) and SNU-C5/5-FUR (0.72 ± 0.01-fold) cells, while cyclin B1 levels did not change considerably (Fig. 2B).

 Fenbendazole induced apoptosis <italic>via</italic> caspase-3-PARP pathway in CRC cells

The cell death effects were identified via annexin V/PI staining after incubation with fenbendazole in SNU-C5 and SNU-C5/5-FUR cells (Fig. 3A). Cell death analysis showed a significant increase in the fraction of apoptosis and necrosis was found in both CRC cells compared with vehicle-treated cells (Fig. 3A). The fraction of SNU-C5 cells in early (1.24 ± 0.15% vs. 14.34 ± 0.26%) and late (3.95 ± 0.14% vs. 14.30 ± 0.08%) apoptosis along with the fraction of SNU-C5/5-FUR cells in early (0.25 ± 0.03% vs. 3.27 ± 0.14%) and late (1.83 ± 0.07% vs. 10.77 ± 0.72%) apoptosis showed a significant upward trend. The fraction of SNU-C5 (2.05 ± 0.09% vs. 7.59 ± 0.36%) and SNU-C5/5-FUR (1.40 ± 0.08% vs. 3.16 ± 0.16%) cells in necrosis also showed a significant upward trend.

Western blot revealed that the activation (cleaved/full length) of PARP was significantly increased in SNU-C5 (1.79 ± 0.11-fold) and SNU-C5/5-FUR (2.28 ± 0.03-fold) cells. The activation (cleaved/total form) of caspase-3 was significantly increased in SNU-C5 (1.44 ± 0.10-fold) and SNU-C5/5-FUR (2.18 ± 0.09-fold) cells. The level of cytochrome-C showed a significant increase in SNU-C5 (1.37 ± 0.17-fold) and SNU-C5/5-FUR (1.37 ± 0.08-fold) cells (Fig. 3B).

 Fenbendazole did not activate other cell death pathways in CRC cells

Western blot on autophagy proteins revealed that Beclin-1 expression was significantly increased in SNU-C5 (1.35 ± 0.02-fold) and SNU-C5/5-FUR (1.46 ± 0.07-fold) cells. LC3-I level increased slightly in SNU-C5 (1.13 ± 0.13-fold) cells but remained unchanged in SNU-C5/5-FUR cells. Atg7 expression increased considerably in SNU-C5 (1.53 ± 0.07-fold) and in SNU-C5/5-FUR (1.12 ± 0.06-fold) cells. Atg16L1 levels increased slightly in SNU-C5/5-FUR (1.21 ± 0.04-fold) but remained unchanged in SNU-C5 cells. Other markers were not changed considerably in both CRC cells (Fig. 4).

Western blot on ferroptosis proteins revealed that GPX4 showed significantly decreased levels in SNU-C5 (0.60 ± 0.02-fold) and SNU-C5/5-FUR (0.71 ± 0.05-fold) cells. FTH1 levels increased significantly in SNU-C5 (5.44 ± 0.32-fold) and SNU-C5/5-FUR (3.48 ± 0.54-fold) cells. FPN showed a significant increase in SNU-C5 (1.77 ± 0.07-fold) and SNU-C5/5-FUR (1.59 ± 0.10-fold) cells. The levels of SLC7A11 increased slightly in SNU-C5 (1.19 ± 0.05-fold) cells but decreased significantly in SNU-C5/5-FUR (0.67 ± 0.02-fold) cells. The expression of transferrin receptor remained unchanged in both CRC cells. HMGB1, a member of damage-associated molecular patterns (DAMP), showed significantly increased levels in SNU-C5 (1.30 ± 0.10-fold) and SNU-C5/5-FUR (2.36 ± 0.06-fold) cells (Fig. 5A).

The effects of anti-ferroptotic agents, ferrostatin-1 and DFOM, were evaluated in fenbendazole-induced ferroptosis (Fig. 5B). Ferrostatin-1 co-treatment did not increase the viability of both CRC cells. Concentrations greater than 1 μM paradoxically decreased the cell viability in SNU-C5 (69.60 ± 4.85% vs. 47.10 ± 1.71%) and SNU-C5/5-FUR (75.95 ± 2.20% vs. 49.97 ± 1.15%) cells following co-treatment. Co-treatment with DFOM did not increase the viability of the CRC cells. High concentration (10 μM) of DFOM paradoxically decreased the viability of SNU-C5 (60.14 ± 2.11% vs. 35.33 ± 1.10%) and SNU-C5/5-FUR (73.04 ± 1.96% vs. 60.58 ± 1.61%) cells.

Western blot on necroptotic proteins revealed that the activation (phosphor/total) of RIP was significantly increased in SNU-C5 (2.31 ± 0.21-fold) and SNU-C5/5-FUR (4.72 ± 0.32-fold) cells. The activation of RIP3 was significantly decreased in SNU-C5 (0.42 ± 0.00-fold) and SNU-C5/5-FUR (0.47 ± 0.04-fold) cells. The activation of MLKL was not changed considerably in both CRC cells (Fig. 6). While the full length of caspase-8 was not changed in both CRC cells, the significant increase was observed in the active cleaved fragment in SNU-C5 (2.45 ± 0.21-fold) cells and the cleaved intermediate fragment in SNU-C5/5-FUR (1.22 ± 0.07-fold) cells (Fig. 6).

 Fenbendazole activated p53 on SNU-C5 cells, but not on SNU-C5/5-FUR cells

The activation (phosphor/total form) of p53 was significantly increased in SNU-C5 (1.17 ± 0.05-fold) cells, but the activation of p38, ERK, and JNK did not change. The activation of p53, p38 (0.83 ± 0.02-fold), ERK, and JNK showed no significant changes in SNU-C5/5-FUR cells (Fig. 7).

 DISCUSSION

As reported previously [1,30], we found that fenbendazole arrests cell cycle at G2/M phase and induces apoptosis via p53-p21 pathways in SNU-C5 and SNU-C5/5-FUR cells. Cell death pathways were further investigated in terms of apoptosis, autophagy, ferroptosis, and necroptosis to identify the differences in 5-FU resistance. Benzimidazoles induce apoptosis via caspase-3-PARP activation [1], which is also true in SNU-C5 and SNU-C5/5-FUR cells with the increased levels of mitochondrial injury marker, cytochrome-C. Benzimidazole is historically known to bind beta-tubulin, disrupt microtubules, and arrest cell division [1,30,33-35]. Although Beclin-1 was increased in SNU-C5 and SNU-C5/5-FUR cells, autophagy might be not so effective due to insufficient LC3 (II/I) activation especially in SNU-C5/5-FUR cells.

Benzimidazole-induced ferroptosis has yet to be fully reported. Ferroptosis is characterized by lipid peroxidation. It can be induced by the accumulation of free iron and via the inactivation of cysteine uptake by SLC7A11 or the inactivation of the lipid repair enzyme GPX4 [36-38]. Free iron level might be regulated (decreased) by the increased expression of FTH1 (storage) and FPN (exporter), whereas decreased expression of GPX4 and/or SLC7A11 induces ferroptosis in SNU-C5 and SNU-C5/5-FUR cells. The effects of anti-ferroptotic agents were elucidated to establish ferroptosis as main cell death pathway in fenbendazole treatment. Treatment with ferrostatin-1 (the inhibitor of SLC7A11-dependent ferroptosis) and DFOM (the iron chelating agent to inhibit ferroptosis) did not effectively block the fenbendazole-induced cell viability, suggesting that ferroptosis is not the primary cell death pathway in fenbendazole-induced anti-cancer effects. However, ferroptosis-inducing agents trigger synergistic apoptosis by increasing DAMP as reported in HCT116 cells [39].

Benzimidazole-related necroptosis has yet to be investigated comprehensively. Necroptosis is negatively regulated by caspases and initiated by a complex containing of RIP and RIP3 kinases, leading to phosphorylation of MLKL [40-42]. In this study, MLKL activation was not affected by fenbendazole treatment, and thus necroptosis was not effectively activated in both CRC cells. But active and intermediate form of caspase-8 was increased in SNU-C5 and SNU-C5/5-FUR cells, respectively, which induces apoptosis via cytochrome-C or caspase-3 [43].

During MAPK signaling, benzimidazole usually inhibits ERK activation [7,44], but increases p38 [5,35] and JNK activation [5,23,33,35,45]. Interestingly, ERK-dependent activation of heat shock factor-1 (HSF-1) promotes chemotherapeutic resistance to benzimidazole (parbendazole and nocodazole) in HCT116 and RKO cells. Biochemical inhibition of HSF-1 results in significant enhancement of drug potency. Therefore, Wales et al. [34] suggested that targeting ERK signaling pathway is a potential strategy in benzimidazole-resistant CRC cells. Despite the contrasting ERK response to yeast extract treatment in SNU-C5 and SNU-C5/5-FUR cells [19], we found no significant changes on p38, ERK and JNK, signaling after fenbendazole treatment.

Benzimidazole is known to activate p53 and p21 but decrease mutant p53 expression [30,46]. Cancer cells with wild-type p53 showed higher sensitivity to fenbendazole compared with p53 mutant cells [5,35]. In addition to cell cycle arrest via p53-p21 pathways [1,30,47], p53 acts as a key metabolic switch in cellular function and death [48-50]. In this study, fenbendazole induces G2/M arrest and apoptosis in both 5-FU-sensitive SNU-C5 and SNU-C5/5-FUR CRC cells. In SNU-C5 cells, fenbendazole is presumed to activate p53-mediated apoptosis by increasing p53 expression, and partly necrosis, autophagy and ferroptosis (Fig. 8A). P53 activation is mainly associated with mitochondrial injury and caspase-3-dependent apoptosis, of which caspase-3 activation might be partly induced by caspase-8 and Beclin-1. In addition, ferroptosis by decreased GPX4 might augment apoptosis as previously described [39]. In SNU-C5/5-FUR cells, fenbendazole triggers apoptosis without affecting p53 expression (Fig. 8B), which was characterized by the following differences as compared with SNU-C5 cells. The expression of LC3, Atg7, and active caspase-8 was not increased, which resulted in reduced autophagy and caspase-8-dependent apoptosis. The expression of SLC7A11 as well as GPX4 was suppressed, which resulted in ferroptosis as previously reported [51,52]. As a result, apoptosis was partly induced by Beclin-1, and further augmented by ferroptosis in SNU-C5/5-FUR cells than in SNU-C5 cells. However, the activation of p53 with benzimidazole treatment is still disputed. Benzimidazole induces concurrent apoptosis and pyroptosis of human glioblastoma cells as well as inhibits cell cycle via p53-p21 pathway [53], while mebendazole was associated with p53-independent induction of p21 and tubule depolymerization in ovarian cancer [54]. Therefore, cell-type specific activation of p53 should be identified prior to benzimidazole, including fenbendazole, treatment of various cancers.

Taken together, SNU-C5/5-FUR cells exhibited approximately 10-fold higher IC50 values with fenbendazole compared with SNU-C5 cells, but still showed cytotoxicity at micromolar concentrations as previously reported [35]. Fenbendazole induces apoptosis as well as cell cycle arrest at G2/M phase via p53-p21 pathways in CRC cells. In case of cell death, fenbendazole induces primarily apoptotic cell death rather than autophagy, ferroptosis, and necroptosis. Although fenbendazole has anti-cancer effects on both 5-FU-sensitive and resistant CRC cells, the mechanism of action appears to be different. That is, fenbendazole promotes cell death by activating p53-mediated apoptosis in SNU-C5 cells, whereas by both enhancing p53-independent apoptosis and ferroptosis-augmented apoptosis in SNU-C5/5-FUR cells. Therefore, further studies are needed to identify sensitive and resistant cancer cell types to facilitate cell type-specific treatment with benzimidazole.

 ACKNOWLEDGEMENTS

None.

FUNDING

This work was supported by a research grant from the Jeju National University Hospital Research Fund of Jeju National University School of Medicine in 2020.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

 REFERENCES SonDS LeeES AdunyahSE 2020 The antitumor potentials of benzimidazole anthelmintics as repurposing drugs Immune Netw 20 e29 10.4110/in.2020.20.e29 32895616 PMC7458798 MukhopadhyayT SasakiJ RameshR RothJA 2002 Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo Clin Cancer Res 8 2963 2969 12231542 SasakiJ RameshR ChadaS GomyoY RothJA MukhopadhyayT 2002 The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells Mol Cancer Ther 1 1201 1209 12479701 MartarelliD PompeiP BaldiC MazzoniG 2008 Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice Cancer Chemother Pharmacol 61 809 817 10.1007/s00280-007-0538-0 17581752 DograN MukhopadhyayT 2012 Impairment of the ubiquitin-proteasome pathway by methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate leads to a potent cytotoxic effect in tumor cells: a novel antiproliferative agent with a potential therapeutic implication J Biol Chem 287 30625 30640 10.1074/jbc.M111.324228 22745125 PMC3436308 LinS YangL YaoY XuL XiangY ZhaoH WangL ZuoZ HuangX ZhaoC 2019 Flubendazole demonstrates valid antitumor effects by inhibiting STAT3 and activating autophagy J Exp Clin Cancer Res 38 293 10.1186/s13046-019-1303-z 31287013 PMC6615228 3e2c66b97c604ee1b9fbb07e1c470dc9 MichaelisM AghaB RothweilerF LöschmannN VogesY MittelbronnM StarzetzT HarterPN AbhariBA FuldaS WestermannF RieckenK SpekS LangerK WieseM DirksWG ZehnerR CinatlJ WassMN CinatlJJr 2015 Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen Sci Rep 5 8202 10.1038/srep08202 25644037 PMC4314641 HeoDS 2020 Anthelmintics as potential anti-cancer drugs? J Korean Med Sci 35 e75 10.3346/jkms.2020.35.e75 32056406 PMC7025903 YamaguchiT ShimizuJ OyaY HorioY HidaT 2021 Drug-induced liver injury in a patient with nonsmall cell lung cancer after the self-administration of fenbendazole based on social media information Case Rep Oncol 14 886 891 10.1159/000516276 34248555 PMC8255718 ChiangRS SyedAB WrightJL MontgomeryB inlavsSSr 2021 Fenbendazole enhancing anti-tumor effect: a case series Clin Oncol Case Rep 4 2 https://www.scitechnol.com/peer-review/fenbendazole-enhancing-antitumor-effect-a-case-series-P3SV.pdf BrayF FerlayJ SoerjomataramI SiegelRL TorreLA JemalA 2018 Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394 424 Erratum in: CA Cancer J Clin. 2020;70:313 10.3322/caac.21492 30207593 AzwarS SeowHF AbdullahM Faisal JabarM MohtarrudinN 2021 Recent updates on mechanisms of resistance to 5-fluorouracil and reversal strategies in colon cancer treatment Biology (Basel) 10 854 10.3390/biology10090854 34571731 PMC8466833 63c56935834c487a856258521353921b PanMH LaiCS WuJC HoCT 2011 Molecular mechanisms for chemoprevention of colorectal cancer by natural dietary compounds Mol Nutr Food Res 55 32 45 10.1002/mnfr.201000412 21207511 FridmanJS LoweSW 2003 Control of apoptosis by p53 Oncogene 22 9030 9040 10.1038/sj.onc.1207116 14663481 LiXL ZhouJ ChenZR ChngWJ 2015 P53 mutations in colorectal cancer- molecular pathogenesis and pharmacological reactivation World J Gastroenterol 21 84 93 10.3748/wjg.v21.i1.84 25574081 PMC4284363 ThorntonTM RinconM 2009 Non-classical p38 map kinase functions: cell cycle checkpoints and survival Int J Biol Sci 5 44 51 10.7150/ijbs.5.44 19159010 PMC2610339 GrossiV PesericoA TezilT SimoneC 2014 p38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance World J Gastroenterol 20 9744 9758 10.3748/wjg.v20.i29.9744 25110412 PMC4123363 KimEJ KangJI KwakJW 2015 The anticancer effect of (1S,2S,3E,7E,11E)-3,7,11, 15-cembratetraen-17,2-olide(LS-1) through the activation of TGF-β signaling in SNU-C5/5-FU, fluorouracil-resistant human colon cancer cells Mar Drugs 13 1340 1359 10.3390/md13031340 25786063 PMC4377987 MoonD KangHK KimJ YoonSP 2020 Yeast extract induces apoptosis and cell cycle arrest via activating p38 signal pathway in colorectal cancer cells Ann Clin Lab Sci 50 31 44 32161010 ArkunY 2016 Dynamic modeling and analysis of the cross-talk between insulin/AKT and MAPK/ERK signaling pathways PLoS One 11 e0149684 10.1371/journal.pone.0149684 26930065 PMC4773096 NygrenP FryknäsM AgerupB LarssonR 2013 Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer J Cancer Res Clin Oncol 139 2133 2140 10.1007/s00432-013-1539-5 24135855 PMC3825534 Al-DouhMH SahibHB OsmanH Abd HamidS SalhimiSM 2012 Anti-proliferation effects of benzimidazole derivatives on HCT-116 colon cancer and MCF-7 breast cancer cell lines Asian Pac J Cancer Prev 13 4075 4079 10.7314/APJCP.2012.13.8.4075 23098519 ChenK ChuBZ LiuF LiB GaoCM LiLL SunQS ShenZF JiangYY 2015 New benzimidazole acridine derivative induces human colon cancer cell apoptosis in vitro via the ROS-JNK signaling pathway Acta Pharmacol Sin 36 1074 1084 10.1038/aps.2015.44 26235743 PMC4561968 KrálováV HanušováV RudolfE ČáňováK SkálováL 2016 Flubendazole induces mitotic catastrophe and senescence in colon cancer cells in vitro J Pharm Pharmacol 68 208 218 10.1111/jphp.12503 26730435 HanušováV SkálováL KrálováV MatouškováP 2018 The effect of flubendazole on adhesion and migration in SW480 and SW620 colon cancer cells Anticancer Agents Med Chem 18 837 846 10.2174/1871520618666171213141911 29237383 WilliamsonT BaiRY StaedtkeV HusoD RigginsGJ 2016 Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model Oncotarget 7 68571 68584 10.18632/oncotarget.11851 27612418 PMC5356574 DuanQ LiuY RockwellS 2013 Fenbendazole as a potential anticancer drug Anticancer Res 33 355 362 23393324 PMC3580766 DoudicanN RodriguezA OsmanI OrlowSJ 2008 Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells Mol Cancer Res 6 1308 1315 10.1158/1541-7786.MCR-07-2159 18667591 BaiRY StaedtkeV AprhysCM GalliaGL RigginsGJ 2011 Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme Neuro Oncol 13 974 982 10.1093/neuonc/nor077 21764822 PMC3158014 MrkvováZ UldrijanS PombinhoA BartůněkP SlaninováI 2019 Benzimidazoles downregulate Mdm2 and MdmX and activate p53 in MdmX overexpressing tumor cells Molecules 24 2152 10.3390/molecules24112152 31181622 PMC6600429 TangY LiangJ WuA ChenY ZhaoP LinT ZhangM XuQ WangJ HuangY 2017 Co-delivery of trichosanthin and albendazole by nano-self-assembly for overcoming tumor multidrug-resistance and metastasis ACS Appl Mater Interfaces 9 26648 26664 Erratum in: ACS Appl Mater Interfaces. 2020;12:3275 10.1021/acsami.7b05292 28741923 KimJW KimSH MariappanR MoonD KimJ YoonSP 2021 Anti-cancer effects of the aqueous extract of Orostachys japonica A. Berger on 5-fluorouracil-resistant colorectal cancer via MAPK signalling pathways in vitro and in vivo J Ethnopharmacol 280 114412 10.1016/j.jep.2021.114412 34265383 FengR LiS LuC AndreasC StolzDB MaparaMY LentzschS 2011 Targeting the microtubular network as a new antimyeloma strategy Mol Cancer Ther 10 1886 1896 10.1158/1535-7163.MCT-11-0234 21825007 WalesCT TaylorFR HigaAT McAllisterHA JacobsAT 2015 ERK-dependent phosphorylation of HSF1 mediates chemotherapeutic resistance to benzimidazole carbamates in colorectal cancer cells Anticancer Drugs 26 657 666 10.1097/CAD.0000000000000231 25811962 DograN KumarA MukhopadhyayT 2018 Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways Sci Rep 8 11926 10.1038/s41598-018-30158-6 30093705 PMC6085345 YangWS iRamaratnamRSr WelschME ShimadaK SkoutaR ViswanathanVS CheahJH ClemonsPA ShamjiAF ClishCB BrownLM GirottiAW CornishVW SchreiberSL StockwellBR 2014 Regulation of ferroptotic cancer cell death by GPX4 Cell 156 317 331 10.1016/j.cell.2013.12.010 24439385 PMC4076414 Friedmann AngeliJP SchneiderM PronethB TyurinaYY TyurinVA HammondVJ HerbachN AichlerM WalchA EggenhoferE BasavarajappaD RådmarkO KobayashiS SeibtT BeckH NeffF EspositoI WankeR FörsterH YefremovaO 2014 Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice Nat Cell Biol 16 1180 1191 10.1038/ncb3064 25402683 PMC4894846 Latunde-DadaGO 2017 Ferroptosis: role of lipid peroxidation, iron and ferritinophagy Biochim Biophys Acta Gen Subj 1861 1893 1900 10.1016/j.bbagen.2017.05.019 28552631 LeeYS LeeDH JeongSY ParkSH OhSC ParkYS YuJ ChoudryHA BartlettDL LeeYJ 2019 Ferroptosis-inducing agents enhance TRAIL-induced apoptosis through upregulation of death receptor 5 J Cell Biochem 120 928 939 10.1002/jcb.27456 30160785 PMC6249082 KaczmarekA VandenabeeleP KryskoDV 2013 Necroptosis: the release of damage-associated molecular patterns and its physiological relevance Immunity 38 209 223 10.1016/j.immuni.2013.02.003 23438821 CaiZ JitkaewS ZhaoJ ChiangHC ChoksiS LiuJ WardY WuLG LiuZG 2014 Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis Nat Cell Biol 16 55 65 Erratum in: Nat Cell Biol. 2014;16:200 10.1038/ncb2883 24316671 PMC8369836 NirmalaJG LopusM 2020 Cell death mechanisms in eukaryotes Cell Biol Toxicol 36 145 164 10.1007/s10565-019-09496-2 31820165 ZhongB LiuM BaiC RuanY WangY QiuL HongY WangX LiL LiB 2020 Caspase-8 induces lysosome-associated cell death in cancer cells Mol Ther 28 1078 1091 10.1016/j.ymthe.2020.01.022 32053770 PMC7132614 YounisNS GhanimAMH SaberS 2019 Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma Sci Rep 9 19095 10.1038/s41598-019-55666-x 31836811 PMC6911098 ZhangF LiY ZhangH HuangE GaoL LuoW WeiQ FanJ SongD LiaoJ ZouY LiuF LiuJ HuangJ GuoD MaC HuX LiL QuX ChenL 2017 Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC) Oncotarget 8 12968 12982 10.18632/oncotarget.14673 28099902 PMC5355070 XuD TianW JiangC HuangZ ZhengS 2019 The anthelmintic agent oxfendazole inhibits cell growth in non-small cell lung cancer by suppressing c-Src activation Mol Med Rep 19 2921 2926 10.3892/mmr.2019.9897 MirzayansR AndraisB ScottA MurrayD 2012 New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy J Biomed Biotechnol 2012 170325 10.1155/2012/170325 22911014 PMC3403320 WangDB KinoshitaC KinoshitaY MorrisonRS 2014 p53 and mitochondrial function in neurons Biochim Biophys Acta 1842 1186 1197 10.1016/j.bbadis.2013.12.015 24412988 PMC4074561 MoulderDE HatoumD TayE LinY McGowanEM 2018 The roles of p53 in mitochondrial dynamics and cancer metabolism: the pendulum between survival and death in breast cancer? Cancers (Basel) 10 189 10.3390/cancers10060189 29890631 PMC6024909 TangD KangR BergheTV VandenabeeleP KroemerG 2019 The molecular machinery of regulated cell death Cell Res 29 347 364 10.1038/s41422-019-0164-5 30948788 PMC6796845 KangR KroemerG TangD 2019 The tumor suppressor protein p53 and the ferroptosis network Free Radic Biol Med 133 162 168 10.1016/j.freeradbiomed.2018.05.074 29800655 PMC6251771 LeiG MaoC YanY ZhuangL GanB 2021 Ferroptosis, radiotherapy, and combination therapeutic strategies Protein Cell 12 836 857 10.1007/s13238-021-00841-y 33891303 PMC8563889 RenLW LiW ZhengXJ LiuJY YangYH LiS ZhangS FuWQ XiaoB WangJH DuGH 2022 Benzimidazoles induce concurrent apoptosis and pyroptosis of human glioblastoma cells via arresting cell cycle Acta Pharmacol Sin 43 194 208 10.1038/s41401-021-00752-y 34433903 ElayapillaiS RamrajS BenbrookDM BieniaszM WangL PathuriG IsingizweZR KennedyAL ZhaoYD LightfootS HunsuckerLA GundersonCC 2021 Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer Gynecol Oncol 160 302 311 10.1016/j.ygyno.2020.10.010 33131904 PMC8820236 Figures Anti-cancer effects of fenbendazole in colorectal cancer cells.

(A) The SNU-C5 and 5-FU-resistant SNU-C5 (SNU-C5/5-FUR) cells were mock-treated with dimethyl sulfoxide (DMSO) or treated with indicated concentrations of fenbendazole or albendazole for 3 days. The extent of cell viability was determined by MTT assay as described in Methods. Data are presented as mean ± SD. **p < 0.01 and ***p < 0.001 vs. DMSO. #p < 0.05, ##p < 0.01, and ###p < 0.001 vs. SNU-C5. (B) The SNU-C5 and SNU-C5/5-FUR cells were mock-treated with DMSO or treated with indicated doses of fenbendazole for indicated days. Cell viability was determined as described in (A). (C) Representative images of SNU-C5 and SNU-C5/5-FUR cells treated with fenbendazole. Scale bar = 200 μm.

 Fenbendazole-induced cell cycle arrest at G2/M phase with increased p21 expression in colorectal cancer cells.

(A) Cell cycle distribution in SNU-C5 and SNU-C5/5-FUR cells were assessed by flow cytometry after treatment with mock (dimethyl sulfoxide, DMSO) or indicated dose of fenbendazole for 3 days. The percentages of cells in each phase for SNU-C5 (left) and SNU-C5/5-FUR (right) cells are presented as the mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. DMSO. (B) SNU-C5 (left) and SNU-C5/5-FUR (right) cells were mock-treated with DMSO or treated with indicated dose of fenbendazole. 3 days after treatment, cells were harvested and whole cell extracts were subjected to immunoblotting using the indicated antibodies. Signal intensities of p27, p21, Cyclin B1, and C-Myc were measured by AzureSpot analysis software. Data are presented as the mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. DMSO.

 Fenbendazole-induced apoptosis <italic>via</italic> mitochondrial injury and caspase-3-poly (ADP-ribose) polymerase (PARP) pathways in colorectal cancer cells.

(A) Cell death distribution was assessed by annexin V/PI staining and flow cytometry after treatment with mock (dimethyl sulfoxide, DMSO) or indicated dose of fenbendazole for 3 days. The percentages of normal, early apoptosis, late apoptosis, and necrosis in SNU-C5 (left) and SNU-C5/5-FUR (right) cells are presented as the mean ± SD. **p < 0.01 and ***p < 0.001 vs. DMSO. (B) SNU-C5 and SNU-C5/5-FUR cells were mock-treated with DMSO or treated with indicated dose of fenbendazole. 3 days after treatment, cells were harvested and whole cell extracts were subjected to immunoblotting using the anti-PARP, anti-caspase-3, and anti-cytochrome C antibodies. Signal intensity of each proteins was measured by AzureSpot analysis software. Data are presented as the mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. DMSO.

 Fenbendazole-induced autophagy <italic>via</italic> beclin-1 in colorectal cancer cells.

Effect of fenbendazole on the expression of autophagy-related proteins in SNU-C5 and SNU-C5/5-FUR cells was detected by immunoblotting. SNU-C5 and SNU-C5/5-FUR cells were mock-treated with dimethyl sulfoxide (DMSO) or treated with indicated dose of fenbendazole for 3 days. Total protein was collected, and immunoblotting analysis was performed for light chain 3 (LC3) (I/II), Beclin-1, Atg16L1, Atg3, Atg5, Atg12 (detected Atg12-5 complex also), and Atg7. GAPDH was used for a loading control. Band density was analyzed by AzureSpot analysis software, and results are expressed as the mean ± SD. *p < 0.05, **p < 0.01 vs. DMSO.

 Fenbendazole-induced ferroptosis <italic>via</italic> glutathione peroxidase 4 (GPX4) in colorectal cancer cells.

(A) Effect of fenbendazole on the expression of ferroptosis-related proteins in SNU-C5 and SNU-C5/5-FUR cells was detected by immunoblotting. SNU-C5 and SNU-C5/5-FUR cells were mock-treated with dimethyl sulfoxide (DMSO) or treated with indicated dose of fenbendazole for 3 days. Total protein was collected, and immunoblotting analysis was performed for GPX4, high mobility group box 1 (HMGB1), SCL7A11, ferritin heavy chain (FTH1), ferroportin (FPN), and transferrin receptor (TfRC). GAPDH was used for a loading control. Band density was analyzed by AzureSpot analysis software, and results are expressed as the mean ± SD. *p < 0.05, **p < 0.01 vs. DMSO. (B) The SNU-C5 and SNU-C5/5-FUR cells were treated with fenbendazole alone or with fenbendazole in combination with indicated doses of ferrostatin-1 or deferoxamine mesylate (DFOM) for 3 days. The extent of cell viability was determined by MTT assay. Data are presented as mean ± SD.

 Fenbendazole-induced necroptosis in colorectal cancer cells.

Effect of fenbendazole on the expression of necroptosis-related proteins in SNU-C5 and SNU-C5/5-FUR cells was detected by immunoblotting. SNU-C5 and SNU-C5/5-FUR cells were mock-treated with dimethyl sulfoxide (DMSO) or treated with indicated dose of fenbendazole for 3 days. Total protein was collected, and immunoblotting analysis was performed for phospho-receptor-interacting protein kinase (pRIP), RIP, pRIP3, RIP3, phosphor-mixed lineage kinase domain-like protein (pMLKL), MLKL, and caspase-8. GAPDH was used for a loading control. Band density was analyzed by AzureSpot analysis software, and results are expressed as the mean ± SD. *p < 0.05, **p < 0.01 vs. DMSO.

 Fenbendazole-induced p53 activation in colorectal cancer cells.

SNU-C5 and SNU-C5/5-FUR cells were mock-treated with dimethyl sulfoxide (DMSO) or treated with indicated dose of fenbendazole. 3 days after treatment, cells were harvested and whole cell extracts were subjected to immunoblotting using the indicated antibodies. Signal intensity of each proteins was measured by AzureSpot analysis software. Data are presented as the mean ± SD. *p < 0.05 vs. DMSO.

 Schematic representation of cell death pathways in colorectal cancer (CRC) cells following fenbendazole treatment.

Fenbendazole induces G2/M arrest and apoptosis in both (A) 5-FU-sensitive SNU-C5 and (B) 5-FU-resistant SNU-C5 (SNU-C5/5-FUR) CRC cells. In SNU-C5 cells, fenbendazole is presumed to activate p53-mediated apoptosis by increasing p53 expression. In SNU-C5/5-FUR cells, fenbendazole triggers apoptosis without affecting p53 expression, whereas fenbendazole enhances ferroptosis by inhibiting the expression of GPX4 and SLC7A11. Therefore, although fenbendazole has anti-cancer effects on both 5-FU-sensitive and resistant CRC cells, the mechanism of action appears to be different. That is, fenbendazole promotes cell death by activating p53-mediated apoptosis in SNU-C5 cells, whereas by both enhancing p53-independent apoptosis and ferroptosis-augmented apoptosis in SNU-C5/5-FUR cells. PARP, poly (ADP-ribose) polymerase; HMGB1, high mobility group box 1; GPX4, glutathione peroxidase 4; LC3, light chain 3.